Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model

• DOI: 10.3389/fphar.2023.1228525
• Publication Date: 2023-07-28T16:26:04Z
• Authors: Ahmed Abd-Eltawab...; Waleed Y. Rizg; Amy Fakhry Boushra; Maha Alhelf; Mohammed Alissa; Ghada F. Soliman; Ghada Nady Ouais; Khaled M. Hosny; Hala M. Alkhalidi; Ahmed Magdy Elebiary
• Keywords: Telmisartan

Objective: Telmisartan is an angiotensin receptor blocker (ARB) that specifically blocks II type-1 receptors (AT1R). has been proven to have antidiabetic effects via a variety of mechanisms, and it can be utilized in some diabetic patients due its dual benefit for hypertensive with type 2 DM (T2DM) when the other oral medications are intolerable or contraindicated. However, precise underlying hypoglycemic mechanism still obscure. Aim work: We sought establish link between telmisartan administration myostatin expression skeletal muscles T2DM rat model as potential telmisartan. Materials Methods: 32 male albino rats were included study; 8 served controls (group I). was inducted 24 rats, which then randomly subdivided into 3 groups (8 each): II) Diabetic group (groups III IV) treated either mg/kg/day) metformin (250 respectively gavage 4-week period. Results: resulted significant improvement OGTT, HOMA-IR, glucose uptake, muscle mass/body ratios compared (p < 0.05). Additionally, induced boost adiponectin IL-10 serum levels substantial drop TNF-α IL-6 Moreover, significantly boosted SOD GSH, decreased MDA group. Furthermore, downregulation upregulation insulin receptor, IRS-1, IRS-3 genes also detected. Histologically, attenuated morphological damage fibers evidenced by considerable decrease collagen deposition area percentage reduction NF-kB tissues III. Conclusion: dramatically reduced expressions muscles, improved resistance uptake these highlighting novel treating T2DM.